Ponesimod
Sponsors
Actelion, Janssen Pharmaceutica N.V., Belgium, Biogen, Vanda Pharmaceuticals
Conditions
Chronic Graft Versus Host DiseaseHealthyModerate-to-severe Chronic Plaque PsoriasisMultiple SclerosisUlcerative Colitis (UC)
Phase 1
Phase 2
Phase 3
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
CompletedNCT02425644
Start: 2015-06-04End: 2019-05-16Updated: 2025-03-30
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
TerminatedNCT02907177
Start: 2017-03-30End: 2020-03-26Updated: 2021-05-18
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
CompletedNCT03232073
Start: 2017-07-05End: 2024-01-16Updated: 2025-06-22
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
RecruitingNCT07362017
Start: 2026-02-17End: 2028-12-01Target: 300Updated: 2026-06-11
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
Not yet recruitingNCT07686081
Start: 2026-09-01End: 2029-08-01Target: 150Updated: 2026-07-07